TD Asset Management Inc. lifted its position in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 10.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 80,151 shares of the biotechnology company’s stock after acquiring an additional 7,300 shares during the period. TD Asset Management Inc. owned 0.22% of Spark Therapeutics worth $7,146,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in ONCE. Teachers Advisors LLC grew its position in shares of Spark Therapeutics by 1.9% during the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after acquiring an additional 650 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Spark Therapeutics by 9.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 87,751 shares of the biotechnology company’s stock worth $4,681,000 after acquiring an additional 7,605 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Spark Therapeutics by 81.6% in the second quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock worth $1,507,000 after purchasing an additional 11,335 shares during the period. C WorldWide Group Holding A S lifted its holdings in Spark Therapeutics by 16.6% in the second quarter. C WorldWide Group Holding A S now owns 52,281 shares of the biotechnology company’s stock worth $3,123,000 after purchasing an additional 7,449 shares during the period. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Spark Therapeutics in the second quarter worth about $829,000. Institutional investors and hedge funds own 94.94% of the company’s stock.
In other Spark Therapeutics news, insider Daniel Faga sold 6,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $82.50, for a total value of $495,000.00. Following the completion of the sale, the insider now directly owns 6,000 shares of the company’s stock, valued at approximately $495,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Barge Joseph La sold 5,500 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $71.44, for a total transaction of $392,920.00. Following the completion of the sale, the insider now directly owns 8,146 shares of the company’s stock, valued at $581,950.24. The disclosure for this sale can be found here. Insiders sold a total of 1,077,809 shares of company stock valued at $90,559,445 over the last three months. 7.30% of the stock is owned by corporate insiders.
Shares of Spark Therapeutics Inc (NASDAQ ONCE) opened at $68.64 on Tuesday. Spark Therapeutics Inc has a 1-year low of $47.03 and a 1-year high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. During the same period in the previous year, the company posted ($1.07) earnings per share. Spark Therapeutics’s revenue was up 45.8% compared to the same quarter last year. equities analysts forecast that Spark Therapeutics Inc will post -7.6 earnings per share for the current fiscal year.
Several research firms recently weighed in on ONCE. BMO Capital Markets reaffirmed a “buy” rating and issued a $101.00 price objective on shares of Spark Therapeutics in a report on Wednesday, November 15th. ValuEngine downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Royal Bank Of Canada reduced their price objective on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating for the company in a report on Wednesday, November 8th. SunTrust Banks set a $101.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. Finally, Barclays upped their price objective on shares of Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a report on Friday, October 13th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and eighteen have issued a buy rating to the stock. Spark Therapeutics has an average rating of “Buy” and a consensus target price of $90.36.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/12/05/td-asset-management-inc-purchases-7300-shares-of-spark-therapeutics-inc-once.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.